Timothy Anderson of Prudential Equities, who has an "overweight" rating on Wyeth, pointed to a number of potential pitfalls in a note this morning.

FORBES: Wyeth's Blowout Quarter

In a report last week, Tim Anderson, a sell-side analyst at Prudential Equities group, predicted that the Premarin trial would be ending early (see " Wyeth's Premarin Trial Seen Ending Early").

FORBES: Wyeth Lucks Out On Hormone Study

In a note to investors this morning, Prudential Equities analyst Timothy Anderson wrote that he is unconvinced about the benefits of scale for drugmakers like Novartis and Pfizer (nyse: PFE - news - people ).

FORBES: If Novartis Steps In, Will Pfizer Follow?